Innovation in bone healing and tissue repair

28 Jun 16
valuationLAB Initiates Research Coverage on Kuros
Schlieren (Zurich), Switzerland, June 28, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that independent life science research boutique valuationLAB has issued its first report on Kuros. The research analyst estimates a current......READ MORE
23 Jun 16
First Trading Day of New Kuros Share after Reverse Split
Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced the first trading day of the new shares after a reverse split at the ratio of 100 to 1 approved by the recent Annual Shareholders’ Meeting. ......READ MORE
16 Jun 16
Kuros Bioscience’s Shareholders Approve All Resolutions
Kuros Biosciences Ltd (“Kuros”) today announced that its shareholders approved all resolutions at the Annual Shareholders’ Meeting 2016. In particular, they voted with a large majority for the proposed reverse stock split at the......READ MORE
26 May 16
Kuros Invites to the Annual Shareholders’ Meeting 2016
Schlieren (Zurich), Switzerland, May 26, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that the Annual Shareholders’ Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Com-pany’s offices in Schlieren/Zurich......READ MORE
26 Apr 16
Kuros Biosciences Reports Financial Results for 2015
Three extraordinary one-time factors lead to positive result for 2015 Debt-free balance sheet after mandatory conversion of bonds and settlement with convertible loan note holders ......READ MORE
20 Apr 16
Kuros receives milestone payment from Checkmate
Kuros Biosciences Ltd. (“Kuros” or the “Company”), has been informed by Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) that the first melanoma patient has been dosed in a Phase 1b clinical trial with CMP-001, formerly known as......READ MORE
08 Mar 16
Kuros Biosciences Ltd. appoints Chief Medical Officer
Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect. Dr. Jamieson has spent over 25 years in......READ MORE
20 Jan 16
Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd.
Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”) today announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all......READ MORE
08 Jan 16
Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers
Cytos Biotechnology Ltd announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of......READ MORE
06 Jan 16
Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
Cytos Biotechnology Ltd announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting with overwhelming majority. These resolutions, among other things, consist of an ordinary capital......READ MORE

Kuros Biosciences AG
Wagistrasse 25, 8952 Schlieren, Switzerland
Tel: +41 (0)44 200 56 00   Fax: +41 (0)44 200 56 01   Email: info@kuros.ch

About Kuros

  1. Overview
  2. Management
  3. Board
  • Careers

    Products

    1. Pipeline
    2. Sealants
      Surgical sealants
      KUR-023
    3. Orthobiologics
      Fracture repair
      KUR-111
      KUR-113
      Spinal fusion
      KUR-113

    Technologies

    1. Overview
    2. Fibrin-based
    3. Synthetic-based
    4. Immune modulation
    5. Publications

    Partnerships

    1. Collaborations
    2. Business development

    Investors

    1. Share price
    2. Regulatory filings
    3. Reports & presentations
    4. Calendar
    5. Corporate governance
    6. Stay informed

    News & Events

    1. Press releases
    2. Conferences & Events

    Contact

    1. Location
  • Press releases

    28 Jun 16
    valuationLAB Initiates Research Coverage on Kuros
    Schlieren (Zurich), Switzerland, June 28, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that independent life science research boutique valuationLAB has issued its first report on Kuros. The research analyst estimates a current......READ MORE
    23 Jun 16
    First Trading Day of New Kuros Share after Reverse Split
    Schlieren (Zurich), Switzerland, June 23, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced the first trading day of the new shares after a reverse split at the ratio of 100 to 1 approved by the recent Annual Shareholders’ Meeting. ......READ MORE
    16 Jun 16
    Kuros Bioscience’s Shareholders Approve All Resolutions
    Kuros Biosciences Ltd (“Kuros”) today announced that its shareholders approved all resolutions at the Annual Shareholders’ Meeting 2016. In particular, they voted with a large majority for the proposed reverse stock split at the......READ MORE
    26 May 16
    Kuros Invites to the Annual Shareholders’ Meeting 2016
    Schlieren (Zurich), Switzerland, May 26, 2016 – Kuros Biosciences Ltd (“Kuros”) today announced that the Annual Shareholders’ Meeting 2016 will take place on Thursday, June 16, 2016 at 1 p.m. at the Com-pany’s offices in Schlieren/Zurich......READ MORE
    26 Apr 16
    Kuros Biosciences Reports Financial Results for 2015
    Three extraordinary one-time factors lead to positive result for 2015 Debt-free balance sheet after mandatory conversion of bonds and settlement with convertible loan note holders ......READ MORE
    20 Apr 16
    Kuros receives milestone payment from Checkmate
    Kuros Biosciences Ltd. (“Kuros” or the “Company”), has been informed by Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) that the first melanoma patient has been dosed in a Phase 1b clinical trial with CMP-001, formerly known as......READ MORE
    08 Mar 16
    Kuros Biosciences Ltd. appoints Chief Medical Officer
    Kuros Biosciences Ltd. (“Kuros” or the “Company”), announced today that Dr. Virginia Jamieson has been appointed Chief Medical Officer and member of the Executive Board with immediate effect. Dr. Jamieson has spent over 25 years in......READ MORE
    20 Jan 16
    Kuros Biosurgery Holding Ltd. closes merger with Cytos Biotechnology Ltd. which is renamed Kuros Biosciences Ltd.
    Kuros Biosciences Ltd. (SIX:KURN formerly CYTN) (“Kuros”) today announced the closing of the acquisition of Kuros Biosurgery Holding Ltd. and the change of name of the combined company to Kuros Biosciences Ltd. Starting 20 January 2016 all......READ MORE
    08 Jan 16
    Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers
    Cytos Biotechnology Ltd announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of......READ MORE
    06 Jan 16
    Extraordinary Shareholders’ Meeting of Cytos Biotechnology Ltd. approves all resolutions
    Cytos Biotechnology Ltd announced today that its shareholders have approved all resolutions at today’s Extraordinary Shareholders’ Meeting with overwhelming majority. These resolutions, among other things, consist of an ordinary capital......READ MORE